Hi, it’s Michelle in New York. You may have heard of “Ozempic blindness,” when obesity drugs are linked to rare vision loss. Does this discovery change the risk-benefit analysis for the drugs? More in a moment, but first …
In June, EU regulators said that people with type 2 diabetes taking semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, are at risk of developing a rare eye condition that can cause vision loss. This could possibly affect as many as 1 in 10,000 people taking the medicine.